Ellen is a senior associate who focuses her practice on securities litigation, including shareholder class actions and opt-outs thereto, business disputes, investigations, and crisis management. She has experience taking and defending depositions, drafting briefs and other filings, as well as representing clients in internal investigations and interfacing with various government entities including the U.S. Department of Justice and the U.S. Securities and Exchange Commission. Ellen has represented companies and individuals in a variety of industries, including life sciences and financial services.
Ellen also has an active pro bono practice. To date, she has successfully represented an individual seeking asylum, a Section 8 tenant facing eviction, and a domestic violence shelter.
Prior to joining Mintz , Ellen was a litigation associate at a leading global law firm’s New York headquarters, where she worked on securities litigation and complex commercial cases, including for Fortune 500 companies.
While attending law school, Ellen was a legal intern for a New York-based civil rights lawyer, focusing on First Amendment matters and other issues. She also served on the executive board and as a submissions editor for the Harvard Journal of Law & Gender and as a primary editor for the Harvard Human Rights Journal.
- Harvard Law School (JD)
- Duke University (BA, magna cum laude)
- Represented wellness company and its board members, securing summary judgment, dismissing all federal securities claims pursuant to the Securities Exchange Act of 1934 and the Securities Act of 1933, as well as a breach of contract claim, arising from merger. Summary judgment affirmed by the Second Circuit.
- Represented wellness company and its board members, securing dismissal of all federal securities claims pursuant to the Securities Exchange Act of 1934, breach of contract, and common law fraud claims arising from merger.
- Represented pharmaceutical company and its executives, securing dismissal of all federal securities claims pursuant to the Securities Exchange Act of 1934 and Securities Act 1933, as well as common law claims, in connection with statements concerning pipeline drug. Dismissal affirmed by the Second Circuit.
- Represented financial firm and its executives against Securities Exchange Act of 1934 and Securities Act of 1933 claims in opt-out actions across the country arising out of the 2008 financial crisis.
- Represented investment bank in fee tail dispute to recover fees earned.
- Represented pharmaceutical company against breach of contract claim concerning contingent value right milestones.
- Federal Bar Council, Program Committee, member